Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Elvitegravir

FDA-approved product (tablet, oral), marketed as Vitekta.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Elvitegravir
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • HIV infection
  • HIV-1 infection
  • Viral disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Integrase inhibitors
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AJ02

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA, E. coli and K. pneumoniae. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA47.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli52.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae60.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis58.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Elvitegravir in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.6 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.7 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.0 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Elvitegravir with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Research on the Psychological Status of Patients With HIV-1 Infection

    NCT07080138 · start 2025-08-01

    Registered record
    Registry ID
    NCT07080138
    Conditions
    HIV-1-infection; Anxiety Depression
    Interventions
    All kinds of INSTI medications; All kinds of conventional medications
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Not yet recruiting
    Start
    2025-08-01
    Completion
    2026-12-31
    Enrolment
    500

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1-infection; Anxiety Depression
    InterventionAll kinds of INSTI medications; All kinds of conventional medications
    PhaseNot recorded
    Registry statusNot yet recruiting

  • Study Evaluating the Safety, in Terms of HBV Virological Control At 96 Weeks, of 2 Antiviral Treatment Relief Strategies, in Patients Co-infected with the HIV-1 and HBV Viruses

    NCT06338826 · start 2025-02-01

    Registered record
    Registry ID
    NCT06338826
    Conditions
    HIV Infections; HBV Coinfection
    Interventions
    TDF - 245mg or TAF -25mg associated to 3TC - 300mg or FTC - 200mg and a NNRTI or PI/r or INSTI; Dual therapy with 3TC in combination with DTG or ritonavir-boosted Darunavir (rDVR)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2025-02-01
    Completion
    2027-09-30
    Enrolment
    140

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections; HBV Coinfection
    InterventionTDF - 245mg or TAF -25mg associated to 3TC - 300mg or FTC - 200mg and a NNRTI or PI/r or INSTI; Dual therapy with 3TC in combination with DTG or ritonavir-boosted Darunavir (rDVR)
    PhasePhase 2
    Registry statusNot yet recruiting

  • A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments

    NCT06337032 · start 2024-08-27

    Registered record
    Registry ID
    NCT06337032
    Conditions
    HIV-1-infection
    Interventions
    F/TAF (High Dose Tablet); F/TAF (Low Dose Tablet); F/TAF (Lowest Dose Tablet); F/TAF (High Dose TOS); F/TAF (Low Dose TOS); F/TAF (Lowest Dose TOS); E/C/F/TAF; E/C/F/TAF (Low Dose); Cobicistat (High Dose); Cobicistat (Low Dose); Cobicistat (TOS); B/F/TAF (High Dose); B/F/TAF (Low Dose); B/F/TAF (High Dose TOS); B/F/TAF (Low Dose TOS); B/F/TAF (Lowest Dose TOS); 3rd ARV Agent; Nucleos(t)ide reverse transcriptase inhibitors (NRTI); ATV; DRV; Lopinavir Boosted with ritonavir (LPV/r)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2024-08-27
    Completion
    2034-03
    Enrolment
    350

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1-infection
    InterventionF/TAF (High Dose Tablet); F/TAF (Low Dose Tablet); F/TAF (Lowest Dose Tablet); F/TAF (High Dose TOS) +17 more
    PhasePhase 4
    Registry statusRecruiting

  • Rectal Insert TAF/EVG Pre-Exposure Prophylaxis (RITE PrEP) Study

    NCT06274398 · start 2024-01-16

    Registered record
    Registry ID
    NCT06274398
    Conditions
    Safety Issues
    Interventions
    TAF/EVG rectal insert; Matching placebo rectal insert
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2024-01-16
    Completion
    2025-05-16
    Enrolment
    21

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSafety Issues
    InterventionTAF/EVG rectal insert; Matching placebo rectal insert
    PhasePhase 1
    Registry statusCompleted

  • Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen

    NCT05502341 · start 2022-08-16

    Registered record
    Registry ID
    NCT05502341
    Conditions
    HIV-1-infection
    Interventions
    Bictegravir; Lenacapavir; BIC/LEN FDC; Stable Baseline Regimen
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Active not recruiting
    Start
    2022-08-16
    Completion
    2028-07
    Enrolment
    689

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1-infection
    InterventionBictegravir; Lenacapavir; BIC/LEN FDC; Stable Baseline Regimen
    PhasePhase 2 / Phase 3
    Registry statusActive not recruiting

  • A Study of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Evaluated as a Fixed Dose Combination Regimen in Participants Switching From an Integrase Inhibitor Who Have Experienced Rapid Weight Gain

    NCT04442737 · start 2020-07-01

    Registered record
    Registry ID
    NCT04442737
    Conditions
    HIV-1
    Interventions
    D/C/F/TAF FDC; TAF/FTC FDC; INI Based Regimen
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2020-07-01
    Completion
    2023-08-30
    Enrolment
    103

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1
    InterventionD/C/F/TAF FDC; TAF/FTC FDC; INI Based Regimen
    PhasePhase 4
    Registry statusCompleted

  • Same-Day Treatment With Genvoya vs. EFV/TDF/3TC

    NCT03405194 · start 2018-05-01

    Registered record
    Registry ID
    NCT03405194
    Conditions
    HIV/AIDS
    Interventions
    Elvitegravir, Cobicistat, TAF, FTC; Efavirenz, TDF, and 3TC
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Withdrawn
    Start
    2018-05-01
    Completion
    2020-07-01
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV/AIDS
    InterventionElvitegravir, Cobicistat, TAF, FTC; Efavirenz, TDF, and 3TC
    PhaseNot applicable
    Registry statusWithdrawn

  • A Clinical Trial to Evaluate the Efficacy and Safety of Elvitegravir / Cobicistat / Emtricitabine / Tenofovir Alafenamide as a First-line Treatment in Naïve Patients With HIV-1 Infection With Severe Immunosuppression

    NCT03693508 · start 2018-04-13

    Registered record
    Registry ID
    NCT03693508
    Conditions
    HIV Infections; Severe Immunosuppression
    Interventions
    Genvoya®
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2018-04-13
    Completion
    2020-05-28
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections; Severe Immunosuppression
    InterventionGenvoya®
    PhasePhase 4
    Registry statusCompleted

  • Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide as Maintenance Treatment for HIV/HBV-coinfection

    NCT03425994 · start 2018-02-06

    Registered record
    Registry ID
    NCT03425994
    Conditions
    Chronic Hepatitis B in HIV Patient; Kidney Injury; Bone Diseases
    Interventions
    Elvitegravir/Cobicistat/Emtricitabine
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2018-02-06
    Completion
    2019-10-11
    Enrolment
    275

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Hepatitis B in HIV Patient; Kidney Injury; Bone Diseases
    InterventionElvitegravir/Cobicistat/Emtricitabine
    PhaseNot recorded
    Registry statusUnknown

  • Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients

    NCT03256422 · start 2017-09-07

    Registered record
    Registry ID
    NCT03256422
    Conditions
    HIV Infections
    Interventions
    Treatment discontinuation
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2017-09-07
    Completion
    2020-03-02
    Enrolment
    640

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionTreatment discontinuation
    PhasePhase 3
    Registry statusCompleted

  • Prevention and Treatment Continuum for Youth at HIV Risk, Acutely Infected and With Established HIV Infection

    NCT03205696 · start 2017-08-01

    Registered record
    Registry ID
    NCT03205696
    Conditions
    Human Immunodeficiency Virus
    Interventions
    Antiretrovirals
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2017-08-01
    Completion
    2023-11-30
    Enrolment
    101

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHuman Immunodeficiency Virus
    InterventionAntiretrovirals
    PhaseNot recorded
    Registry statusCompleted

  • Evaluation of Compliance With Treatment by Genvoya in HIV Post-exposure Prophylaxis

    NCT02998320 · start 2017-03-10

    Registered record
    Registry ID
    NCT02998320
    Conditions
    HIV Risk
    Interventions
    Genvoya
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2017-03-10
    Completion
    2018-09-30
    Enrolment
    101

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Risk
    InterventionGenvoya
    PhasePhase 3
    Registry statusCompleted

  • Switch From Dual Regimens Based on Dolutegravir Plus a Reverse Transcriptase Inhibitor to E/C/F/TAF in Virologically Suppressed, HIV-1 Infected Patients (Be-OnE)

    NCT03493568 · start 2017-02-06

    Registered record
    Registry ID
    NCT03493568
    Conditions
    HIV-1-infection
    Interventions
    Genvoya 150Mg-150Mg-200Mg-10Mg Tablet; Dolutegravir 50 mg plus one RTI
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2017-02-06
    Completion
    2020-07-31
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1-infection
    InterventionGenvoya 150Mg-150Mg-200Mg-10Mg Tablet; Dolutegravir 50 mg plus one RTI
    PhasePhase 3
    Registry statusTerminated

  • Early ART to Limit Infection and Establishment of Reservoir

    NCT02859558 · start 2017-01-24

    Registered record
    Registry ID
    NCT02859558
    Conditions
    HIV-1 Infection
    Interventions
    elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide or bictegravir/emtricitabine/tenofovir alafenamide or other medically-appropriate FDA-approved antiretroviral therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2017-01-24
    Completion
    2025-04-16
    Enrolment
    195

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1 Infection
    Interventionelvitegravir/cobicistat/emtricitabine/tenofovir alafenamide or bictegravir/emtricitabine/tenofovir alafenamide or other medically-appropriate FDA-approved antiretroviral therapy
    PhasePhase 2
    Registry statusCompleted

  • Efficacy, Safety, and Tolerability of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Participants Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV Treatment

    NCT02707601 · start 2016-04-01

    Registered record
    Registry ID
    NCT02707601
    Conditions
    HIV-1 Infection; HCV Infection
    Interventions
    E/C/F/TAF; F/R/TAF; LDV/SOF
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2016-04-01
    Completion
    2017-09-29
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1 Infection; HCV Infection
    InterventionE/C/F/TAF; F/R/TAF; LDV/SOF
    PhasePhase 3
    Registry statusCompleted